Patents by Inventor Ute Splittgerber

Ute Splittgerber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8484873
    Abstract: The subject matter of the current invention is directed to a front-loading display system adapted for safe, frequent, and rapid change of displayed objects. The display system includes a base and an object-holding assembly. The object-holding assembly can be releasably attached to the base through the use of a fastener, which allows the base to remain mounted to a mounting surface when changing display objects. In a preferred embodiment, the fastener employs magnetic force to connect the base and the object-holding assembly. The display object is retained between a resting plate and a cover plate, the two plates being releasably attached to each other by the use of at least one holding device, which may be selected from clips, clasps, hinges and elastic bands.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: July 16, 2013
    Inventor: Ute Splittgerber
  • Patent number: 8481536
    Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: July 9, 2013
    Assignee: TargeGen, Inc.
    Inventors: Xianchang Gong, Kathy Barrett, Jianguo Cao, Colleen Gritzen, Glenn Noronha, John D. Hood, Chi Ching Mak, Andrew McPherson, Ved Prakash Pathak, Joel Renick, Richard M. Soll, Ute Splittgerber, Wolfgang Wrasidlo, Binqi Zeng, Ningning Zhao, Elena Dneprovskaia
  • Publication number: 20110294796
    Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: December 28, 2010
    Publication date: December 1, 2011
    Applicant: TargeGen, Inc.
    Inventors: Xianchang Gong, Kathy Barrett, Jianguo Cao, Colleen Gritzen, John D. Hood, Chi Ching Mak, Andrew McPherson, Ved Prakash Pathak, Joel Renick, Richard M. Soll, Ute Splittgerber, Wolfgang Wrasidlo, Ningning Zhao, Elena Dneprovskaia, Binqi Zeng, Glenn Noronha
  • Publication number: 20100330030
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
    Type: Application
    Filed: May 14, 2010
    Publication date: December 30, 2010
    Applicant: TargeGen, Inc.
    Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
  • Publication number: 20100278811
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
    Type: Application
    Filed: December 1, 2009
    Publication date: November 4, 2010
    Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
  • Publication number: 20090275569
    Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: September 9, 2008
    Publication date: November 5, 2009
    Inventors: Xianchang Gong, Kathy Barrett, Jianguo Cao, Colleen Gritzen, Glenn Noronha, John D. Hood, Chi Ching Mak, Andrew McPherson, Ved Prakash Pathak, Joel Renick, Richard M. Soll, Ute Splittgerber, Wolfgang Wrasidlo, Ningning Zhao, Elena Dneprovskaia, Binqi Zeng, Glenn Noronha
  • Publication number: 20090099097
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.
    Type: Application
    Filed: November 7, 2008
    Publication date: April 16, 2009
    Applicant: Yale University
    Inventors: Craig M. Crews, Mikael Elofsson, Ute Splittgerber, Kyung Bo Kim
  • Patent number: 7476650
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: January 13, 2009
    Assignee: Yale University
    Inventors: Craig M. Crews, Mikael Elofsson, Ute Splittgerber, Kyung Bo Kim
  • Patent number: 7456176
    Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: April 7, 2005
    Date of Patent: November 25, 2008
    Assignee: TargeGen, Inc.
    Inventors: Glenn Noronha, Kathy Barrett, Jianguo Cao, Colleen Gritzen, Xianchang Gong, John D. Hood, Chi Ching Mak, Andrew McPherson, Ved Prakash Pathak, Joel Renick, Richard M. Soll, Ute Splittgerber, Wolfgang Wrasidlo, Binqi Zeng, Ningning Zhao, Elena Dneprovskaia
  • Publication number: 20070208019
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
    Type: Application
    Filed: January 11, 2007
    Publication date: September 6, 2007
    Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
  • Publication number: 20070204500
    Abstract: The subject matter of the current invention is directed to a front-loading display system adapted for safe, frequent, and rapid change of displayed objects. The display system includes a base and an object-holding assembly. The object-holding assembly can be releasably attached to the base through the use of a fastener, which allows the base to remain mounted to a mounting surface when changing display objects. In a preferred embodiment, the fastener employs magnetic force to connect the base and the object-holding assembly. The display object is retained between a resting plate and a cover plate, the two plates being releasably attached to each other by the use of at least one holding device, which may be selected from clips, clasps, hinges and elastic bands.
    Type: Application
    Filed: March 1, 2007
    Publication date: September 6, 2007
    Inventor: Ute Splittgerber
  • Patent number: 7208493
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: April 24, 2007
    Assignee: TargeGen, Inc.
    Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
  • Publication number: 20060247250
    Abstract: The invention provides pyrimidine compounds having formula A. The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: March 15, 2006
    Publication date: November 2, 2006
    Applicant: TargeGen, Inc.
    Inventors: Jianguo Cao, Richard Soll, Glenn Noronha, Kathy Barrett, Colleen Gritzen, John Hood, Chi Mak, Andrew McPherson, Ved Pathak, Joel Renick, Ute Splittgerber, Binqi Zeng
  • Publication number: 20050282814
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
    Type: Application
    Filed: April 13, 2005
    Publication date: December 22, 2005
    Applicant: TargeGen, Inc.
    Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
  • Publication number: 20050245524
    Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: April 7, 2005
    Publication date: November 3, 2005
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Kathy Barrett, Jianguo Cao, Colleen Gritzen, Xianchang Gong, John Hood, Chi Mak, Andrew McPherson, Ved Pathak, Joel Renick, Richard Soll, Ute Splittgerber, Wolfgang Wrasdilo, Ningning Zhao, Elena Dneprovskaia
  • Publication number: 20040266664
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.
    Type: Application
    Filed: June 17, 2004
    Publication date: December 30, 2004
    Applicant: Yale University
    Inventors: Craig M. Crews, Mikael Elofsson, Ute Splittgerber, Kyung Bo Kim
  • Patent number: 6831099
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.
    Type: Grant
    Filed: May 11, 2000
    Date of Patent: December 14, 2004
    Assignee: Yale University
    Inventors: Craig M. Crews, Mikael Elofsson, Ute Splittgerber, Ny Sin, Kyung Bo Kim
  • Publication number: 20040167198
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
    Type: Application
    Filed: October 2, 2003
    Publication date: August 26, 2004
    Applicant: TargeGen, Inc.
    Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao